Cytek Biosciences, Inc.

NASDAQ:CTKB

Medical - Devices

Healthcare
$5.92 -2.64%

-$0.11 today

Market cap
$774.24M
Beta
1.19
P/E (TTM)
-6.7
EPS (TTM)
-$0.57
52W Low $2.90High $6.18

Volume 1.05M

Average 0.88M

CTKB Operating Expenses

Total costs of running the business that are not directly tied to producing goods or services sold.

Cytek Biosciences, Inc.NASDAQ: CTKB

Operating Expenses · Q1 FY2026 · quarter ended Mar 2026

Operating expenses grows in line with its trailing trend

Q1 FY2026 operating expenses of $39.72M rose 13.1% year over year, ahead of the +12.3% change in trailing-twelve-month operating expenses. Sequentially, it rose 3.2% from the prior quarter. Over 3 fiscal years it compounded at +12.1% a year.

Context

  • Operating expenses amounted to 71.9% of revenue in FY2025, up 6.2 pp from a year earlier.
  • Operating expenses increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +13.1% holds above the trailing-twelve-month pace of +12.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$39.72M+3.2% QoQ
Last fiscal yearDec 2025
$144.84M+10.0% YoY
LTMMar 2026
$149.43M+12.3% YoY
Operating Expenses past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+13.1%——
1 year+10.0%——
3-year CAGR+12.1%——
5-year CAGR——
10-year CAGR——

Operating Expenses history

USD · from the income statement

Latest · FY2025
144.84M USD
Year-over-year change
+10.0%
4-year CAGR
+19.9%

Operating Expenses vs competitors

How CTKB compares with its peers on the latest reported figures

  • CTKB's LTM Mar 2026 operating expenses of $149.43M is the 5th highest of the 6 companies compared; the peer median is $1.11B.
  • Its year-over-year change of +12.3% is the highest of 6, against a peer median of -1.5%.
  • Operating expenses amounts to 73.2% of revenue for CTKB, versus a peer median of 43.1%.
CTKB Competitors Peer median
Operating Expenses for CTKB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AAgilent Technologies, Inc.LTM Jul 2026$2.32B +7.9%+0.9%31.5%
BRKRBruker CorporationLTM Jun 2026$1.51B +2.0%+15.4%43.1%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$1.11B -1.5%-0.2%42.8%
TXG10x Genomics, Inc.LTM Sep 2026$516.85M -3.0%-0.5%83.6%
CTKBCytek Biosciences, Inc.LTM Mar 2026$149.43M +12.3%+12.1%73.2%
LABStandard BioTools Inc.LTM Mar 2026$120.17M -35.3%-3.9%139.3%
Peer median (excluding CTKB) $1.11B-1.5%-0.2%43.1%

Competitors are the stored peer set for CTKB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue127.95M164.04M193.02M200.45M201.49M
Cost of Revenue48.81M63.06M83.59M89.35M97.03M
Gross Profit79.14M100.97M109.43M111.11M104.46M
Gross Margin61.9%61.6%56.7%55.4%51.8%
Research & Development24.44M34.86M44.15M39.4M36.47M
Selling, General & Admin45.55M67.92M93.12M92.23M108.38M
Operating Expenses69.99M102.78M137.27M131.63M144.84M
Depreciation & Amortization1.24M5.66M9.23M10.49M11.98M
EBITDA8.92M9.49M(4.41M)4.79M(17.39M)
EBITDA Margin7.0%5.8%-2.3%2.4%-8.6%
Operating Income9.16M(1.8M)(27.85M)(20.52M)(40.38M)
Operating Margin7.2%-1.1%-14.4%-10.2%-20.0%
Interest Income49K4.62M6.41M10.36M2.22M
Interest Expense1.74M2.57M2.07M0474K
Other Income / Expenses(3.22M)3.06M12.14M14.82M10.54M
Income Before Tax5.94M1.26M(15.71M)(5.7M)(29.84M)
Pre-Tax Margin4.6%0.8%-8.1%-2.8%-14.8%
Income Tax Expense2.91M(1.22M)(3.56M)320K36.7M
Net Income3M2.58M(12.15M)(6.02M)(66.54M)
Net Margin2.3%1.6%-6.3%-3.0%-33.0%
EPS (Basic)0.030.02(0.09)(0.05)(0.52)
EPS (Diluted)0.030.02(0.09)(0.05)(0.52)
Weighted Avg Shares133.75M134.51M135.28M130.61M127.75M
Weighted Avg Shares (Diluted)133.75M138.56M135.28M130.61M127.75M

Cytek Biosciences, Inc.

NASDAQ:CTKB

Intrinsic Alpha fair value

Locked

Current Price

$5.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.